Compare EXR & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXR | WAT |
|---|---|---|
| Founded | 1977 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9B | 22.5B |
| IPO Year | 2004 | 1995 |
| Metric | EXR | WAT |
|---|---|---|
| Price | $138.51 | $372.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 17 |
| Target Price | $145.33 | ★ $395.00 |
| AVG Volume (30 Days) | ★ 1.3M | 446.9K |
| Earning Date | 02-19-2026 | 02-12-2026 |
| Dividend Yield | ★ 4.72% | N/A |
| EPS Growth | ★ 14.27 | 3.82 |
| EPS | 4.36 | ★ 10.88 |
| Revenue | ★ $3,421,973,000.00 | $3,105,638,000.00 |
| Revenue This Year | N/A | $7.96 |
| Revenue Next Year | $4.17 | $6.32 |
| P/E Ratio | ★ $31.49 | $35.40 |
| Revenue Growth | 3.34 | ★ 6.90 |
| 52 Week Low | $121.03 | $275.05 |
| 52 Week High | $162.77 | $423.56 |
| Indicator | EXR | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 37.21 |
| Support Level | $136.67 | $386.11 |
| Resistance Level | $141.19 | $401.10 |
| Average True Range (ATR) | 3.35 | 9.85 |
| MACD | -0.71 | -2.00 |
| Stochastic Oscillator | 18.34 | 6.19 |
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 4,000 self-storage properties in 42 states, with over 300 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.